AT1 receptor blockade improves vasorelaxation in experimental renal failure

Hypertension

Volumn 41, Issue 6, 2003, Pages 1364-1371

  Kööbi, Peeter ^a   Kalliovalkama, Jarkko ^b   Jolma, Pasi ^a   Rysä, Jaana ^c   Ruskoaho, Heikki ^c   Vuolteenaho, Olli ^c,d   Kähönen, Mika ^a,b   Tikkanen, Ilkka ^d,e   Fan, Meng ^a   Ylitalo, Pauli ^a,b   Pörsti, Ilkka ^a,d  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

Angiotensin II; Arteries; Endothelium derived factors; Kidney failure; Potassium channels; Receptors

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; APAMIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CHARYBDOTOXIN; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE; LEMAKALIM; LOSARTAN; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN SYNTHASE; ANGIOTENSIN RECEPTOR; N TERMINAL PROATRIAL NATRIURETIC PEPTIDE; N-TERMINAL PROATRIAL NATRIURETIC PEPTIDE; POTASSIUM CHANNEL BLOCKING AGENT; PROTEIN PRECURSOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DILATATION; ARTERY DISEASE; ARTERY ENDOTHELIUM; ARTERY TONE; ARTICLE; AUTORADIOGRAPHY; BLOOD PRESSURE; CONTROLLED STUDY; DRUG MECHANISM; HYPERTENSION; ISOLATED KIDNEY; KIDNEY ARTERY; KIDNEY FAILURE; MALE; MESENTERIC ARTERY; MYOGRAPHY; NEPHRECTOMY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANCE BLOOD VESSEL; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; ANIMAL; AORTA; BIOSYNTHESIS; BLOOD; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HEART VENTRICLE; IN VITRO STUDY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ANIMALS; AORTA; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; HEART VENTRICLES; KIDNEY FAILURE; LOSARTAN; MALE; MESENTERIC ARTERIES; NATRIURETIC PEPTIDE, BRAIN; NEPHRECTOMY; PEPTIDYL-DIPEPTIDASE A; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RNA, MESSENGER; VASOCONSTRICTION; VASODILATION;

EID: 0037781039     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000073782.30879.16     Document Type: Article

References (38)

1. Luke RG. Chronic renal failure: a vasculopathic state. N Engl J Med. 1998;339:841-843.
2. Barenbrock M, Spieker C, Laske V, Heidenreich S, Hohage H, Bachmann J, Hoeks AP, Rahn KH. Studies of the vessel wall properties in hemodialysis patients. Kidney Int. 1994;44:1397-1400.
3. Amann K, Wolf B, Nichols C, Tornig J, Schwarz U, Zeier M, Mall G, Ritz E. Aortic changes in experimental renal failure: hyperplasia or hypertrophy of smooth muscle cells? Hypertension. 1997;29:770-775.
4. Hafner J, Keusch G, Wahl C, Sauter B, Hurlimann A, von Weizsacker F, Krayenbuhl M, Biedermann K, Brunner U, Helfenstein U. Uremic smallartery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol. 1995;33:954-962.
5. Mourad JJ, Girerd X, Boutouyrie P, Laurent S, Safar M, London G. Increased stiffness of radial artery wall material in end-stage renal disease. Hypertension. 1997;30:1425-1430.
6. Rabelink TJ, Koomans HA. Endothelial function and the kidney. Drugs. 1997;53(suppl 1):11-19.
7. van Guldener C, Lambert J, Janssen MJ, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic hemodialysis patients. Nephrol Dial Transplant. 1997;12(suppl 2):14-18.
8. Kalliovalkama J, Jolma P, Tolvanen JP, Kähönen M, Hutri-Kähönen N, Saha H, Tuorila S, Moilanen E, Pörsti I. Potassium channel-mediated vasorelaxation is impaired in experimental renal failure. Am J Physiol. 1999;277:H1622-H1629.
9. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101:1653-1659.
10. Kalliovalkama J, Jolma P, Tolvanen JP, Kähönen M, Hutri-Kähönen N, Wu X, Holm P, Pörsti I. Arterial function in nitric oxide-deficient hyper-tension: influence of long-term angiotensin II receptor antagonism. Cardiovasc Res. 1999;42:773-782.
11. ATP channels by inhibiting steady-state protein kinase A activity and activating protein kinase Cε. J Physiol. 2001;530:193-205.
12. Ca) channels. Hypertension. 2001;37:301-307.
13. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:131-185.
14. Coats P, Johnston F, MacDonald J, McMurray JJ, Hillier C. Endothelium-derived hyperpolarizing factor: identification and mechanisms of action in human subcutaneous resistance arteries. Circulation. 2001;103:1702-1708.
15. Ylitalo P, Hepp R, Oster P, Möhring J, Gross F. Effects of varying sodium intake on blood pressure and renin-angiotensin system in subtotally nephrectomized rats. J Lab Clin Med. 1976;88:807-816.
16. Kalliovalkama J, Kähönen M, Tolvanen JP, Wu X, Voipio J, Pekki A, Doris PA, Ylitalo P, Pörsti I. Arterial responses in vitro and plasma digoxin immunoreactivity after losartan and enalapril treatments in experimental hypertension. Pharmacol Toxicol. 2000;86:36-43.
17. 1 receptor antagonism. J Cardiovasc Pharmacol. 2002;40:478-486.
18. Jolma P, Kalliovalkama J, Tolvanen JP, Kööbi P, Kähönen M, Saha H, Pörsti I. Preserved endothelium-dependent but impaired beta-adrenergic relaxation of the resistance vessels in experimental renal failure. Exp Nephrol. 2002;10:348-354.
19. Laurant P, Touyz RM, Schiffrin EL. Effect of pressurization on mechanical properties of mesenteric small arteries from spontaneously hypertensive rats. J Vasc Res. 1997;34:117-125.
20. Magga J, Marttila M, Mäntymaa P, Vuolteenaho O, Ruskoaho H. Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin- and phenylephrine-infused conscious rats. Endocrinology. 1994;134:2505-2515.
21. Ruskoaho H, Kinnunen P, Taskinen T, Vuolteenaho O, Leppäluoto J, Takala TE. Regulation of ventricular atrial natriuretic peptide release in hypertrophied rat myocardium: effects of exercise. Circulation. 1989;80:390-400.
22. Bäcklund T, Palojoki E, Grönholm T, Eriksson A, Vuolteenaho O, Laine M, Tikkanen I. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapaptrilat in rat in vivo. Pharmacol Res. 2001;44:411-418.
23. Aiello S, Noris M, Todeschini M, Zappella S, Foglieni C, Benigni A, Corna D, Zoja C, Cavallotti D, Remuzzi G. Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int. 1997;52:171-181.
24. Brooks DP, Contino LC. Involvement of nitric oxide synthase in proteinuria associated with chronic renal disease in rats. Pharmacology. 1998;56:257-261.
25. de Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res. 1996;31:7-18.
26. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. J Hypertens. 1992;10:907-912.
27. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev. 1992;44:479-602.
28. Jensen LW, Pedersen EB. Nocturnal blood pressure and relation to vasoactive hormones and renal function in hypertension and chronic renal failure. Blood Press. 1997;6:332-342.
29. Akiba T, Tachibana K, Togashi K, Hiroe M, Marumo F. Plasma human brain natriuretic peptide in chronic renal failure. Clin Nephrol. 1995;44(suppl 1):S61-S64.
30. Morris ST, McMurray JJ, Rodger RS, Jardine AG. Impaired endothelium-dependent vasodilatation in uraemia. Nephrol Dial Transplant. 2000;15:1194-1200.
31. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Abnormalities of endothelial function in patients with predialysis renal failure. Heart. 2000;83:205-209.
32. Busse R, Fleming I. The endothelial organ. Curr Opin Cardiol. 1993;8:719-727.
33. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization beyond nitric oxide and cyctic GMP. Circulation. 1995;92:3337-3349.
34. Mulvany MJ. Vascular remodelling of resistance vessels: can we define this? Cardiovasc Res. 1999;41:9-13.
35. 2 null mutant mice. Kidney Int. 2000;57:570-577.
36. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, and RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
37. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, and the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
38. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.